SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 145 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.57 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $25,198,037 | +1576.8% | 1,735,402 | +2317.0% | 0.39% | +1392.3% |
Q2 2023 | $1,502,774 | -47.3% | 71,800 | -46.8% | 0.03% | -51.9% |
Q1 2023 | $2,851,200 | +181.7% | 135,000 | +192.0% | 0.05% | +390.9% |
Q4 2021 | $1,012,000 | +200.3% | 46,226 | +135.5% | 0.01% | +175.0% |
Q2 2021 | $337,000 | -71.6% | 19,629 | -63.0% | 0.00% | -84.0% |
Q1 2021 | $1,185,000 | +9.5% | 53,000 | +8.8% | 0.02% | 0.0% |
Q4 2020 | $1,082,000 | +134.2% | 48,700 | +55.5% | 0.02% | +127.3% |
Q3 2020 | $462,000 | -88.2% | 31,314 | -88.2% | 0.01% | -91.6% |
Q2 2020 | $3,923,000 | +58.1% | 264,700 | +17.0% | 0.13% | -6.4% |
Q1 2020 | $2,482,000 | +47.6% | 226,200 | +18.1% | 0.14% | +145.6% |
Q4 2019 | $1,682,000 | +345.0% | 191,600 | +279.4% | 0.06% | +200.0% |
Q3 2019 | $378,000 | +0.3% | 50,500 | -40.4% | 0.02% | -36.7% |
Q4 2018 | $377,000 | -10.5% | 84,666 | +62.8% | 0.03% | +30.4% |
Q3 2018 | $421,000 | – | 52,000 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |